Contact Us

Ruth Roberts, Ph.D. Honored for Excellence in Science and Research

AstraZeneca a global research-based biopharmaceutical company
  • <strong>Ruth Roberts, Ph.D.</strong>
  • <strong>..</strong>
  • <strong>..</strong>

With more than 20 years of experience at the interface of science and industry

    CHESHIRE, UNITED KINGDOM, March 5, 2014 /24-7PressRelease/ -- Ruth Roberts, Ph.D., Global Head of Regulatory Safety at AstraZeneca, has been recognized for showing dedication, leadership and excellence in biopharmaceutical research.

With more than 20 years of experience at the interface of science and industry, Dr. Roberts is known for her expertise in innovative approaches to non-clinical drug safety. Daily, she is tasked with overseeing non-clinical toxicology input across the AstraZeneca small molecule portfolio.

AstraZeneca is a global biopharmaceutical company that provides prescription medicines. A company with science and patients at the heart of everything they do, the skills of its employees and company resources are concentrated on those therapy areas in which they believe will make the biggest impact. Specifically, the company focuses on ailments that are prevalent worldwide, such as cancer, cardiovascular/metabolic disease and respiratory/inflammation/autoimmunity. Furthermore, AstraZeneca remains active in infection and neuroscience with targeted investments in opportunities and collaborations.

Well-equipped to explore the various aspects of toxicology and non-clinical strategies, Dr. Roberts earned a Ph.D. in molecular oncology. An avid researcher and science writer, Dr. Roberts has more than 130 published papers and has won several international awards for her contribution to understanding the mechanistic basis of drug and chemical safety, including the Society of Toxicology Achievement award (2002) and the EUROTOX Bo Holmstedt Lectureship Award in 2008.

She recently published a series of papers challenging existing thinking in regulatory strategies in order to reduce safety-related attrition in drug discovery and development and to refine human risk assessment and translation.

She attributes all of her professional success to her hard work, commitment and curiosity.

For more information about AstraZeneca, visit http://www.astrazeneca.com/Home.

About Worldwide Branding
For over 15 years, Worldwide Branding has been the leading, one-stop-shop, personal branding company, both in the United States and abroad. From writing professional biographies and press releases, to creating and driving traffic to personal websites, our team of branding experts tailor each product specifically for our clients needs. We are dedicated to empowering our 600,000 clients with effective branding tools to help them achieve success. From healthcare to finance to education and law, our constituents represent every major industry and occupation, at all career levels.

An international company, we provide our members with access to members in over 52 countries including, the United States, Canada, Australia, the United Kingdom, France, The Netherlands, Germany, Ireland, Spain, Switzerland, South Africa, Belgium, Mexico, Italy, Brazil, Sweden and The United Arab Emirates, just to name a few.

We presently have two offices, but we are headquartered on Long Island. Our team comprises more than 100 staff members and spans 10 key departments.

For more information, please visit http://www.worldwidebranding.com.

Contact:
Ellen Campbell
Director, Media Relations
mediarelations@worldwidebranding.com


# # #

Read more Press Releases from Ellen Campbell:


Comment on this story...

Share This Story


Email this Story

Contact Information


Ellen Campbell
Worldwide Branding

Uniondale, NY
USA
Voice: (516) 833-8440
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.